Continuous reduction of plasma paraoxonase activity with increasing dialysis vintage in hemodialysis patients

Therapeutic Apheresis and Dialysis

Volumn 14, Issue 6, 2010, Pages 572-576

  Henning, Bernhard F ^a,b   Holzhausen, Helge ^a,b   Tepel, Martin ^a,b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Chronic kidney disease; Dialysis vintage; Hemodialysis; Paraoxonase

Indexed keywords

4 NITROPHENYLACETIC ACID; ARYLDIALKYLPHOSPHATASE; PHENYLACETIC ACID; PHENYLACETIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ATHEROGENESIS; CALCULATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIALYSIS; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PHOTOMETRY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY;

ANALYSIS OF VARIANCE; ARYLDIALKYLPHOSPHATASE; CROSS-SECTIONAL STUDIES; ESTERASES; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHENYLACETATES; RENAL DIALYSIS; TIME FACTORS;

EID: 78651492008     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2010.00844.x     Document Type: Article

References (18)

1. Kadkhodaee M, Hemmati M, Zahmatkesh M et al. Assessment of plasma antioxidant status in hemodialysis patients. Ther Apher Dial 2008;12:147-51.
2. Aviram M, Rosenblat M. Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. Methods Mol Biol 2008;477:259-76.
3. Ng CJ, Shih DM, Hama SY, Villa N, Navab M, Reddy ST. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 2005;38:153-63.
4. Bhattacharyya T, Nicholls SJ, Topol EJ et al. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk. JAMA 2008;299:1265-76.
5. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med 2003;34:774-84.
6. Rozenberg O, Shih DM, Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 2005;181:9-18.
7. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-38.
8. Cottone S, Lorito MC, Riccobene R et al. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. J Nephrol 2008;21:175-9.
9. Baráth A, Németh I, Karg E et al. Roles of paraoxonase and oxidative stress in adolescents with uraemic, essential or obesity-induced hypertension. Kidney Blood Press Res 2006;29: 144-51.
10. Haagen L, Brock A. A new automated method for phenotyping arylesterase (EC 3.1.1.2) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clin Biochem 1992;30:391-5.
11. Adkins S, Gan KN, Mody M, La Du BN. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 1993;52:598-608.
12. Dantoine TF, Debord J, Charmes JP et al. Decrease of serum paraoxonase activity in chronic renal failure. J Am Soc Nephrol 1998;9:2082-8.
13. Pankow JS, Folsom AR, Cushman M et al. Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study. Atherosclerosis 2001;154:681-9.
14. Losito A, Kalidas K, Santoni S, Jeffery S. Association of interleukin-6 -174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 2003;64:616-22.
15. Yao Q, Nordfors L, Axelsson J et al. Peroxisome proliferator-activated receptor gamma polymorphisms affect systemic inflammation and survival in end-stage renal disease patients starting renal replacement therapy. Atherosclerosis 2005;182: 105-11.
16. Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atheroscle-rosis development. Free Radic Biol Med 2004;37:1304-16.
17. Rozenberg O, Shih DM, Aviram M. Human serum paraoxonase 1 decreases macrophage cholesterol biosynthesis: possible role for its phospholipase-A2-like activity and lysophosphatidylcholine formation. Arterioscler Thromb Vasc Biol 2003;23: 461-7.
18. Saeed SA, Elsharkawy M, Elsaeed K, Fooda O. Paraoxonase-1 (PON1) activity as a risk factor for atherosclerosis in chronic renal failure patients. Hemodial Int 2008;12:471-9.